LYPLA1 (Gene)

Synonyms:APT-1, APT1, ENTREZ:10434, HGNC:6737, LPL-I, LPL1, LYPLA1, MIM:605599, NM_001279356, NM_001279357, NM_001279358, NM_001279359, NM_001279360, NM_006330, NP_001266285, NP_001266286, NP_001266287, NP_001266288, NP_001266289, NP_006321, XM_005251127, XM_017012956, XM_017012957, XM_017012958, XM_017012959, XM_017012960, XP_005251184, XP_016868445, XP_016868446, XP_016868447, XP_016868448, XP_016868449, XR_001745453, XR_001745454, hAPT1, lysophospholipase 1
Omim:OMIM:605599
Id:3250c41f-ea2d-5a48-b641-308575b07148
Hgnc:HGNC:6737
Entrez:10434
Description:lysophospholipase 1
This gene encodes a member of the alpha/beta hydrolase superfamily. The encoded protein functions as a homodimer, exhibiting both depalmitoylating as well as lysophospholipase activity, and may be involved in Ras localization and signaling. Alternate splicing results in multiple transcript variants. Pseudogenes of this gene have been defined on chromosomes 4, 6, and 7. [provided by RefSeq, Jul 2013]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View LYPLA1's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with LYPLA1.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using LYPLA1.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for LYPLA1.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with LYPLA1.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.